Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
Nature Cancer|May 30, 2024
Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader moleculeLois M Kelly, Justine C Rutter, Kevin H Lin, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Bulletin Du Cancer|September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]Roch Houot, Claire Calmettes, Sophie Park, et al.
NEJM Evidence|June 24, 2025
Intermediate-Dose Cytarabine as Postinduction AML TherapyMathilde Hunault, Cécile Pautas, Sarah Bertoli, et al.
Leukemia|March 6, 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyMaximilian Stahl, Rory M Shallis, Wei Wei, et al.
Blood|June 17, 2018
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapyEdit Porpaczy, Sabrina Tripolt, Andrea Hoelbl-Kovacic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22<sup>+</sup> Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic LeukemiaPatrice Chevallier, Thibaut Leguay, Marc Delord, et al.
Leukemia|May 12, 2026
Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangementBenoit Ducourneau, Arnaud Pages, Stéphanie Struski, et al.
Leukemia|November 14, 2022
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILOPierre-Yves Dumas, Emmanuel Raffoux, Emilie Bérard, et al.
Blood|May 7, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyMartha L Arellano, Michael J Thirman, John F DiPersio, et al.
Pageof 17